Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 12, 2025 07:00 ET | Source: I-Mab Biopharma

I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement

ROCKVILLE, Md., June 12, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (“I-Mab” or the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology...
June 03, 2025 07:00 ET | Source: I-Mab Biopharma

I-Mab to Participate in the H.C. Wainwright “HCW@Home” Series

ROCKVILLE, Md., June 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the...
May 20, 2025 07:00 ET | Source: I-Mab Biopharma

I-Mab to Present at Jefferies Global Healthcare Conference

ROCKVILLE, Md., May 20, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the...
May 15, 2025 07:00 ET | Source: I-Mab Biopharma

I-Mab Reports First Quarter 2025 Financial Results and Provides Business Update

Prioritization of givastomig as I-Mab’s lead program positions the Company for clinical progressNew givastomig combination data selected for mini-oral presentation at ESMO GI, being held July 2-5 in...
April 30, 2025 07:00 ET | Source: I-Mab Biopharma

I-Mab Announces Givastomig Abstract Accepted for Oral Presentation at ESMO GI 2025

ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the...
April 03, 2025 16:01 ET | Source: I-Mab Biopharma

I-Mab Reports Full Year 2024 Financial Results and Provides Business Update

Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) expected in 2H 2025Enrollment completed ahead of schedule in...
March 26, 2025 07:00 ET | Source: I-Mab Biopharma

I-Mab to Present at 24th Annual Needham Virtual Healthcare Conference

ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB), a US-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of...
March 21, 2025 16:30 ET | Source: I-Mab Biopharma

I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

ROCKVILLE, Md., March 21, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (“I-Mab” or the “Company”), announced today that on March 19, 2025 it received a written notice (the “Notice”) from the...
March 07, 2025 07:00 ET | Source: I-Mab Biopharma

I-Mab Announces Accelerated Givastomig Phase 1b Study Progress

Enrollment completed ahead of schedule in the first dose expansion cohortMomentum continues with first patient dosed in the second expansion cohortTopline results from the 40-patient dose expansion...
February 18, 2025 07:00 ET | Source: I-Mab Biopharma

I-Mab to Participate in Leerink Partners Global Healthcare Conference

ROCKVILLE, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a US-based, global biotech company, exclusively focused on the development of precision immune-oncology agents...